Pier Luigi Zinzani

Trials

Studies that name Pier Luigi Zinzani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:30 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT06823960 · Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · recruiting · Marginal Zone Lymphoma(MZL) · principal investigator
• N/A
  NCT06814405 · Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · recruiting · Haematological Malignancy · principal investigator
• N/A
  NCT06814925 · Italian Study of Patients With Lymphoma

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Lymphoma · principal investigator
• N/A
  NCT06806488 · Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Marginal Zone B Cell Lymphoma · principal investigator
• N/A
  NCT06782789 · An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Diffuse Large B Cell Lymphoma (DLBCL) · principal investigator
• N/A
  NCT06781450 · Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Primary Mediastinal B Cell Lymphoma · principal investigator
• N/A
  NCT06781437 · Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · recruiting · Lymphoproliferative Syndrome, Autoimmune, Lymphoma · principal investigator
• N/A
  NCT06781515 · Assessment of Disease Burden in Hairy Cell Leukemia

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Hairy Cell Leukemia · principal investigator
• N/A
  NCT06761274 · Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · recruiting · Hodgkin Lymphoma in Remission · principal investigator
• N/A
  NCT06760936 · Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · active not recruiting · Diffuse Large B Cell Lymphoma (DLBCL) · principal investigator
• N/A
  NCT06734078 · An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · active not recruiting · DLBCL - Diffuse Large B Cell Lymphoma · principal investigator
• N/A
  NCT06733987 · Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · recruiting · Hodgkin Lymphoma · principal investigator
• N/A
  NCT06720870 · An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · unknown · Castleman Disease · principal investigator
• N/A
  NCT06720701 · Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

  IRCCS Azienda Ospedaliero-Universitaria di Bologna · not yet recruiting · Non-Hodgkin Lymphoma · principal investigator
• Ph2
  NCT05977673 · Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

  Fondazione Italiana Linfomi - ETS · recruiting · Hodgkin Lymphoma · principal investigator
• Ph2
  NCT02423291 · A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL

  Fondazione Italiana Linfomi - ETS · completed · Primary Mediastinal Large B Cell Lymphoma · principal investigator
• Ph2
  NCT01822886 · Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

  Fondazione Italiana Linfomi - ETS · completed · Peripheral T-cell Lymphoma · principal investigator
• Ph2
  NCT01611142 · Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

  Kyowa Kirin Co., Ltd. · completed · Peripheral T-Cell Lymphoma · principal investigator
• N/A
  NCT01142674 · T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

  Associazione Angela Serra per la ricerca sul cancro · completed · Lymphoma, T-Cell, Peripheral · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.